Mercatus and GRESB Partner to Improve ESG Data Collection & Reporting Process for Infrastructure Investors
Infrastructure Investor Global Summit Berlin – Mercatus, a leading asset and investment management platform for alternative investors, and GRESB, the global ESG benchmark for real assets, today announced a strategic partnership to accelerate environmental, social and governance (ESG) integration for global infrastructure investors.
More institutional investors than ever before are seeking standardized and validated ESG-related data on their infrastructure investments. Infrastructure managers and operators are also realizing that integrating ESG concerns into business decisions will generate new streams of data that can be used to enhance growth and sustainability.
“ESG has increasingly become a key requirement that customers are demanding we help them solve,” said Tim Buchner, Co-Founder and COO at Mercatus. “At the heart of ESG value creation is data. We are fully aligned with GRESB in our commitment to making the collection, analysis, submission and reporting of ESG and other asset-level data seamless and transparent for real asset investors across the globe.”
The focus of the Mercatus-GRESB partnership is centered on:
- Creating a Data-Driven Approach to ESG that automates data collection, analysis, and submission processes to streamline ESG due diligence and reporting requirements for GRESB’s asset and fund assessments, accelerating value for ESG across the entire LP-GP ecosystem
- Measure the Impact of ESG to better assess the real impact of sustainability on investment performance and decision-making across the infrastructure asset-class
“We are delighted to form this strategic alliance with Mercatus as a GRESB Infrastructure Partner,” says Rick Walters, Director of Infrastructure at GRESB. “As our first infrastructure data partner, we commend Mercatus for taking the lead with infrastructure investment firms managing data down to the asset level and throughout the investment lifecycle. With the GRESB reporting window opening on 1st April 2019, Mercatus is well placed to assist Asset Managers with their upcoming reporting needs.”
Mercatus systematizes and centralizes large volumes of disparate data to give investors and asset owners accurate, real-time analytics on performance, risk, ESG, and more, at the asset, fund, and portfolio levels. The analytics and executive dashboards drive proactive investment decisions based on holistic, data-driven insights.
According to the Global Infrastructure Hub, $94 trillion in global infrastructure investment is needed by 2040. “Climate, social, and other transition risks will have a significant valuation impact for real asset investors,” added Ali Mamujee, Director of Product at Mercatus. “Many of our customers are taking innovative approaches in self-configuring new dashboards in the Mercatus platform to integrate ESG metrics (i.e. health and safety, climate emissions, diversity composition, etc.) within their traditional operational and financial performance reports. The integration of these dashboards and reports has led to cross-functional awareness across the organization to expedite ESG integration and adoption.”
Mark your calendars for our May Webinar!
Sign up to be alerted about the upcoming Mercatus-GRESB May webinar: “Tackling Challenges in ESG Reporting; Satisfying LP Craving for Real-Time Impact”. Speakers and date will be announced shortly.
GRESB is the global environmental, social and governance (ESG) benchmark for real assets. Working in collaboration with the industry, GRESB defines the standard for sustainability performance in real assets providing standardized and validated ESG data to more than 75 institutional investors, representing over USD 18 trillion in institutional capital. In 2018 a record 903 property companies and funds participated in the GRESB Real Estate Assessment, the Infrastructure Assessment covered 75 funds and 280 assets, and 25 portfolios completed the Debt Assessment. Learn more at gresb.com.
Mercatus is the leading provider of alternative asset and investment management solutions, helping investors maximize returns, accelerate growth, and mitigate risk. Mercatus is the only platform to systematically consolidate asset and portfolio data, automate and control financial analysis, and streamline decisions and collaboration across the entire investment lifecycle. Many of the largest global funds leverage Mercatus to manage over $540B of assets and investments across 118 countries and 11 asset classes. Mercatus is headquartered in Silicon Valley with offices in Europe and India. For more information, visit www.gomercatus.com.
+31 20 7740220
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail email@example.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu